Rusfertide Approval Expands Options and Improves Burdens in Polycythemia Vera
Key claim: FDA approved rusfertide (Mimrylo) for polycythemia vera and NCCN now lists it as a Category 1 option for both low- and high-risk PV, expanding choices beyond traditional cytoreductive therapies.
Abstract
FDA approved rusfertide (Mimrylo) for polycythemia vera; updated NCCN guidelines now recommend rusfertide as a Category 1 option for both low- and high-risk PV, expanding treatment choices beyond traditional cytoreductive therapies.
Why this matters
PV is the only MPN subtype where erythrocytosis itself drives thrombosis risk, and until now guideline-endorsed disease control depended on phlebotomy plus hydroxyurea, ropeginterferon, or ruxolitinib. NCCN Category 1 placement of rusfertide across both low- and high-risk PV formally embeds a non-cytoreductive, hepcidin-axis mechanism into the subtype’s standard-of-care algorithm, differentiating PV’s treatment landscape further from ET and MF where no analogous iron-restriction strategy applies.